IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice

Molecular Neurobiology

Volumn 49, Issue 3, 2014, Pages 1126-1142

  Lopes, Carla ^a   Ribeiro, Márcio ^a   Duarte, Ana I ^a   Humbert, Sandrine ^b,c   Saudou, Frederic ^b,c   Pereira De Almeida, Luís ^a,d   Hayden, Michael ^e   Rego, A Cristina ^a,f  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b INSTITUT CURIE   (France)

^c INSERM U1005   (France)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Animal behavior; Energy metabolism; Huntingtin phosphorylation; Huntington's disease; IGF 1; Signaling pathways; YAC128 mice

Indexed keywords

GLUCOSE; HUNTINGTIN; INSULIN; PROTEIN KINASE B; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DYSFUNCTION; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; GLUCOSE METABOLISM; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; MALE; MOTOR DYSFUNCTION; MOUSE; MOUSE STRAIN; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; YAC128 MOUSE; ANIMAL; DRUG EFFECTS; GENETICS; HUMAN; HUNTINGTON DISEASE; INTRANASAL DRUG ADMINISTRATION; MOTOR ACTIVITY; PHYSIOLOGY; TRANSGENIC MOUSE;

ADMINISTRATION, INTRANASAL; ANIMALS; HUMANS; HUNTINGTON DISEASE; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; PHENOTYPE;

EID: 84902546185     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8585-5     Document Type: Article

References (75)

1. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57(5):369-384 (Pubitemid 28237321)
2. MacDonald ME, Gines S, Gusella JF, Wheeler VC (2003) Huntington's disease. Neuromol Med 4(1-2):7-20. doi:10.1385/NMM:4:1-2:7 (Pubitemid 37315182)
3. Landles C, Bates GP (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 5(10):958-963. doi:10.1038/sj.embor.7400250 (Pubitemid 39534452)
4. Ramaswamy S, Shannon KM, Kordower JH (2007) Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant 16(3):301-312 (Pubitemid 47300233)
5. Weydt P, Soyal SM, Gellera C, Didonato S, Weidinger C, Oberkofler H, Landwehrmeyer GB, Patsch W (2009) The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener 4:3. doi:10.1186/1750-1326-4-3
6. Panov AV, Andreeva L, Greenamyre JT (2004) Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: comparison of rat liver and brain mitochondria. Arch Biochem Biophys 424(1):44-52. doi:10.1016/j.abb.2004.01.013 (Pubitemid 38326853)
7. Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci : The Off J Soc Neurosci 28(11):2783-2792. doi:10.1523/JNEUROSCI.0106-08.2008 (Pubitemid 351398886)
8. Ciammola A, Sassone J, Alberti L, Meola G, Mancinelli E, Russo MA, Squitieri F, Silani V (2006) Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ 13(12):2068-2078. doi:10.1038/sj.cdd.4401967 (Pubitemid 44742690)
9. Ferreira IL, Nascimento MV, Ribeiro M, Almeida S, Cardoso SM, Grazina M, Pratas J, Santos MJ, Januario C, Oliveira CR, Rego AC (2010) Mitochondrial-dependent apoptosis in Huntington's disease human cybrids. Exp Neurol 222(2):243 - 255. doi:10.1016/j.expneurol.2010.01.002
10. Ferreira IL, Cunha-Oliveira T, Nascimento MV, Ribeiro M, Proenca MT, Januario C, Oliveira CR, Rego AC (2011) Bioenergetic dysfunction in Huntington's disease human cybrids. Exp Neurol 231(1):127-134. doi:10.1016/j.expneurol.2011. 05.024
11. Ma Y, Eidelberg D (2007) Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol 9(4):223-233. doi:10.1007/s11307-007-0085-4 (Pubitemid 47028738)
12. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 41(2):160-165. doi:10.1002/ana.410410206 (Pubitemid 27082096)
13. Farrer LA (1985) Diabetes mellitus in Huntington disease. Clin Genet 27(1):62-67
14. Podolsky S, Leopold NA (1977) Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 23(1):55-63
15. Group THsDCR (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72(6):971-983
16. Lalic NM, Maric J, Svetel M, Jotic A, Stefanova E, Lalic K, Dragasevic N, Milicic T, Lukic L, Kostic VS (2008) Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65(4):476-480. doi:10.1001/archneur.65.4.476 (Pubitemid 351549955)
17. Boesgaard TW, Nielsen TT, Josefsen K, Hansen T, Jorgensen T, Pedersen O, Norremolle A, Nielsen JE, Hasholt L (2009) Huntington's disease does not appear to increase the risk of diabetes mellitus. J Neuroendocrinol 21(9):770- 776. doi:10.1111/j.1365-2826.2009.01898.x
18. Bjorkqvist M, Fex M, Renstrom E, Wierup N, Petersen A, Gil J, Bacos K, Popovic N, Li JY, Sundler F, Brundin P, Mulder H (2005) The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 14(5):565-574. doi:10.1093/hmg/ddi053 (Pubitemid 40309582)
19. Duarte AI, Petit GH, Ranganathan S, Li JY, Oliveira CR, Brundin P, Bjorkqvist M, Rego AC (2011) IGF-1 protects against diabetic features in an in vivo model of Huntington's disease. Exp Neurol 231(2):314-319. doi:10.1016/j.expneurol.2011.06.016
20. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 12(5):497-508 (Pubitemid 36312929)
21. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35(1):76-83. doi:10.1038/ng1219 (Pubitemid 37048599)
22. Colin E, Regulier E, Perrin V, Durr A, Brice A, Aebischer P, Deglon N, Humbert S, Saudou F (2005) Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 21(6):1478-1488. doi:10.1111/j.1460- 9568.2005.03985.x (Pubitemid 40646594)
23. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2(6):831-837 (Pubitemid 34650078)
24. Alexi T, Hughes PE, van Roon-Mom WM, Faull RL, Williams CE, Clark RG, Gluckman PD (1999) The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. Exp Neurol 159(1):84-97. doi:10.1006/exnr.1999.7168 (Pubitemid 29444905)
25. Vincent AM, Feldman EL (2002) Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 12(4):193-197 (Pubitemid 35230190)
26. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17(24):3837-3846. doi:10.1093/hmg/ddn281 (Pubitemid 352762847)
27. Colin E, Zala D, Liot G, Rangone H, Borrell-Pages M, Li XJ, Saudou F, Humbert S (2008) Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J 27(15):2124-2134. doi:10.1038/emboj.2008.133
28. Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR (2010) Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet 19(8):1528-1538. doi:10.1093/hmg/ ddq026
29. Saleh N, Moutereau S, Azulay JP, Verny C, Simonin C, Tranchant C, El Hawajri N, Bachoud-Levi AC, Maison P (2010) High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology 75(1):57-63. doi:10.1212/WNL.0b013e3181e62076
30. Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X, Krainc D, White MF (2011) IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest 121(10):4070-4081. doi:10.1172/JCI46305
31. Yamamoto A, Cremona ML, Rothman JE (2006) Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol 172(5):719-731. doi:10.1083/jcb.200510065
32. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12(13):1555-1567 (Pubitemid 36857303)
33. Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR (2007) Phenotypic abnormalities in the YAC128mousemodel of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 26(1):189-200. doi:10.1016/j.nbd.2006.12.010 (Pubitemid 46436497)
34. Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I (2008) Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol Dis 31(1):80-88. doi:10.1016/j.nbd.2008.03.010
35. Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH 2nd (2001) Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 187(1-2):91-97 (Pubitemid 32618661)
36. Hanson LR, Frey WH 2nd (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9(3):S5. doi:10.1186/1471- 2202-9-S3-S5
37. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127(2):481 -496. doi:10.1016/j.neuroscience.2004.05.029
38. Standards of medical care in diabetes (2009) Diabetes Care 32(Suppl 1):S13-S61. doi:10.2337/dc09-S013
39. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR (1997) Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88(4):561-572 (Pubitemid 27154421)
40. Carter RJ, Morton J, Dunnett SB (2001) Motor coordination and balance in rodents. Curr Protoc Neurosci Chapter 8:Unit 8 12. doi:10.1002/0471142301. ns0812s15
41. Carrey N, McFadyen MP, Brown RE (2000) Effects of subchronic methylphenidate hydrochloride administration on the locomotor and exploratory behavior of prepubertal mice. J Child Adolesc Psychopharmacol 10(4):277-286 (Pubitemid 32103903)
42. Stocchi V, Cucchiarini L, Magnani M, Chiarantini L, Palma P, Crescentini G (1985) Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Anal Biochem 146(1):118-124 (Pubitemid 15093059)
43. Rego AC, Santos MS, Oliveira CR (1997) Adenosine triphosphate degradation products after oxidative stress and metabolic dysfunction in cultured retinal cells. J Neurochem 69(3):1228-1235 (Pubitemid 27364845)
44. Mitchell IG, Amphlett NW, Rees RW (1994) Parametric analysis of rank transformed data for statistical assessment of genotoxicity data with examples from cultured mammalian cells. Mutagenesis 9(2):125-132 (Pubitemid 24090154)
45. Rosen CJ, Pollak M (1999) Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab 10(4):136-141 (Pubitemid 29284347)
46. Bennett CM, Guo M, Dharmage SC (2007) HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 24(4):333-343. doi:10.1111/j.1464-5491.2007.02106.x (Pubitemid 46452406)
47. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, Lin HC, Yancopoulos GD, Glass DJ (2005) Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 280(4):2737-2744. doi:10.1074/jbc.M407517200 (Pubitemid 40189380)
48. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2(7):e647. doi:10.1371/journal. pone.0000647
49. Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, Lu G, Leavitt BR, Hayden MR (2010) Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J Neurosci 30(43):14318 -14329. doi:10.1523/JNEUROSCI.1589-10.2010
50. Browne SE, Beal MF (2004) The energetics of Huntington's disease. Neurochem Res 29(3):531-546 (Pubitemid 38295004)
51. Bossy-Wetzel E, Petrilli A, Knott AB (2008) Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci 31(12):609-616. doi:10.1016/j.tins. 2008.09.004
52. Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27(11):2803-2820. doi:10.1111/j.1460-9568.2008.06310.x (Pubitemid 351832229)
53. Petersson U, Ostgren CJ, Brudin L, Brismar K, Nilsson PM (2009) Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor Study. Diabetes Metab 35(3):198-205. doi:10.1016/j.diabet.2008.11.003
54. Ataullakhanov FI, Vitvitsky VM (2002) What determines the intracellular ATP concentration. Biosci Rep 22(5-6):501-511 (Pubitemid 36250189)
55. Laviola L, Natalicchio A, Perrini S, Giorgino F (2008) Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans. Am J Physiol Endocrinol Metab 295(5):E991-999. doi:10.1152/ajpendo.90452.2008
56. Vig PJ, Subramony SH, D'Souza DR, Wei J, Lopez ME (2006) Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res Bull 69(5):573-579. doi:10.1016/j.brainresbull.2006.02.020
57. Cai Z, Fan LW, Lin S, Pang Y, Rhodes PG (2011) Intranasal administration of insulin-like growth factor-1 protects against lipopolysaccharide-induced injury in the developing rat brain. Neuroscience 194:195-207. doi:10.1016/j.neuroscience.2011.08.003
58. Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN (2005) Energy balance in early-stage Huntington disease. Am J Clin Nutr 81(6):1335-1341 (Pubitemid 41710235)
59. Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ, Morton AJ, Barker RA (2008) The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study. Exp Neurol 210(2):691-698. doi:10.1016/j.expneurol.2007.12.026
60. Juul A (2003) Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 13(4):113-170
61. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant Nterminal fragment of huntingtin. Hum Mol Genet 8(3):397-407 (Pubitemid 29097327)
62. Josefsen K, Nielsen MD, Jorgensen KH, Bock T, Norremolle A, Sorensen SA, Naver B, Hasholt L (2008) Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J Neuroendocrinol 20(2):165 - 172. doi:10.1111/j.1365-2826.2007.01629.x
63. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40(2):121-127. doi:10.1016/j.mcn.2008.09.007
64. Saleh N, Moutereau S, Azulay JP, Verny C, Simonin C, Tranchant C, El Hawajri N, Bachoud-Levi AC, Maison P, Huntington French Speaking G (2010) High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology 75(1):57-63. doi:10.1212/WNL.0b013e3181e62076
65. Arwert LI, Deijen JB, Drent ML (2005) The relation between insulin-like growth factor I levels and cognition in healthy elderly: a meta-analysis. Growth Horm IGF Res 15(6):416-422. doi:10.1016/j.ghir.2005.09.001 (Pubitemid 41683810)
66. Rosenstock TR, Duarte AI, Rego AC (2010) Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease - from clinical features to the bench. Curr Drug Targets 11(10):1218-1236
67. Milakovic T, Johnson GV (2005)Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280(35):30773-30782. doi:10.1074/jbc.M504749200 (Pubitemid 41291807)
68. Martin WR, Wieler M, Hanstock CC (2007) Is brain lactate increased in Huntington's disease? J Neurol Sci 263(1-2):70-74. doi:10.1016/j.jns.2007.05.035 (Pubitemid 350029836)
69. Wu J, Lin F, Qin Z (2007) Sequestration of glyceraldehyde-3-phosphate dehydrogenase to aggregates formed by mutant huntingtin. Acta Biochim Biophys Sin (Shanghai) 39(11):885-890 (Pubitemid 350136896)
70. Olah J, Klivenyi P, Gardian G, Vecsei L, Orosz F, Kovacs GG, Westerhoff HV, Ovadi J (2008) Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. FEBS J 275(19):4740-4755. doi:10.1111/j.1742-4658.2008.06612.x
71. Sonntag WE, Bennett C, Ingram R, Donahue A, Ingraham J, Chen H, Moore T, Brunso-Bechtold JK, Riddle D (2006) Growth hormone and IGF-I modulate local cerebral glucose utilization and ATP levels in a model of adult-onset growth hormone deficiency. Am J Physiol Endocrinol Metab 291(3):E604- 610. doi:10.1152/ajpendo.00012.2006
72. Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA (2000) Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc Natl Acad Sci U S A 97(18):10236-10241. doi:10.1073/pnas.170008497
73. Grillo CA, Piroli GG, Hendry RM, Reagan LP (2009) Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 1296:35-45. doi:10.1016/j.brainres.2009.08.005
74. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70(6):440-448. doi:10.1212/01.WNL.0000265401.62434.36
75. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5(6):514-516. doi:10.1038/nn849 (Pubitemid 34568991)